The U.S. Food and Drug Administration (FDA) 24 released a new file showing that Johnson & Johnson’s vaccine is highly effective in preventing Wuhan pneumonia (novel coronavirus disease, COVID-19), including against South African and Brazilian variants of the virus. The vaccine has the opportunity to receive FDA emergency authorization for use in the near future.
Large clinical trials have shown that the vaccine is 85.9% effective in the United States, 81.7% effective in South Africa and 87.6% effective in Brazil. An independent panel of the FDA will meet on the 26th to discuss the benefits of the Jovensen vaccine and the potential for subsequent approval of emergency use authorization.
The only FDA-approved vaccines for use against lung disease are Pfizer and Moderna. Although the Joulsen vaccine is slightly less protective than Pfizer and Moderna, the Joulsen vaccine requires only one dose and is stored at refrigerator temperature compared to Pfizer and Moderna, which must be stored at ultra-low temperatures and given two doses.
Single-dose efficacy of 66% U.S. FDA confirms safety and efficacy of Joulsen vaccine
The U.S. Food and Drug Administration (FDA) today (24) an analysis report pointed out that Johnson & Johnson developed a single dose of Wuhan pneumonia (novel coronavirus disease, COVID-19) vaccine safe and effective, for the United States to approve the third vaccine to take the first step.
Only one dose needed to speed up vaccination
According to foreign media reports, scientists at the FDA confirmed that, overall, the Joulsen vaccine is about 66% effective in preventing moderate to severe Wuhan pneumonia and is also safe. It is noteworthy that the Joulsen vaccine requires only one dose instead of two, which can help speed up vaccination.
The report is the first step toward FDA approval of a third vaccine, and the agency’s independent advisory panel will discuss on Friday whether there is sufficient evidence for them to recommend granting emergency use authorization for the vaccine, and if so, the FDA is expected to make a final decision in a few days.
The vaccine is better in the U.S., Latin America and South Africa in a trial of 44,000 people, according to previously announced results, with 72 percent efficacy in the U.S., 66 percent in Latin America and 57 percent in South Africa.
Despite the varying data, the vaccine was highly effective in preventing severe illness in each country, with 85% efficacy, and early studies showed no hospitalizations or deaths 28 days after vaccination.
Recent Comments